These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

57 related articles for article (PubMed ID: 8545744)

  • 1. The pharmacokinetic behaviour of hypoxoside taken orally by patients with lung cancer in a phase I trial.
    Albrecht CF; Kruger PB; Smit BJ; Freestone M; Gouws L; Miller R; van Jaarsveld PP
    S Afr Med J; 1995 Sep; 85(9):861-5. PubMed ID: 8545744
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A phase I trial of hypoxoside as an oral prodrug for cancer therapy--absence of toxicity.
    Smit BJ; Albrecht CF; Liebenberg RW; Kruger PB; Freestone M; Gouws L; Theron E; Bouic PJ; Etsebeth S; van Jaarsveld PP
    S Afr Med J; 1995 Sep; 85(9):865-70. PubMed ID: 8545745
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetic behaviour and cardiovascular effects of intravenously administered hypoxoside and rooperol.
    Coetzee JF; Kruger PB; Albrecht CF; Jahed N; van Jaarsveld PP
    Arzneimittelforschung; 1996 Oct; 46(10):997-1000. PubMed ID: 8931895
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Morphological characterisation of the cell-growth inhibitory activity of rooperol and pharmacokinetic aspects of hypoxoside as an oral prodrug for cancer therapy.
    Albrecht CF; Theron EJ; Kruger PB
    S Afr Med J; 1995 Sep; 85(9):853-60. PubMed ID: 8545743
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Studies on hypoxoside and rooperol analogues from Hypoxis rooperi and Hypoxis latifolia and their biotransformation in man by using high-performance liquid chromatography with in-line sorption enrichment and diode-array detection.
    Kruger PB; Albrecht CF; Liebenberg RW; van Jaarsveld PP
    J Chromatogr B Biomed Appl; 1994 Dec; 662(1):71-8. PubMed ID: 7894695
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase I study of a five-day dose schedule of 4-Ipomeanol in patients with non-small cell lung cancer.
    Kasturi VK; Dearing MP; Piscitelli SC; Russell EK; Sladek GG; O'Neil K; Turner GA; Morton TL; Christian MC; Johnson BE; Kelley MJ
    Clin Cancer Res; 1998 Sep; 4(9):2095-102. PubMed ID: 9748125
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Investigation of the antioxidant activity of African potato (Hypoxis hemerocallidea).
    Nair VD; Dairam A; Agbonon A; Arnason JT; Foster BC; Kanfer I
    J Agric Food Chem; 2007 Mar; 55(5):1707-11. PubMed ID: 17295502
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetics of low-dose doxorubicin and metabolites in patients with AIDS-related Kaposi sarcoma.
    Joerger M; Huitema AD; Meenhorst PL; Schellens JH; Beijnen JH
    Cancer Chemother Pharmacol; 2005 May; 55(5):488-96. PubMed ID: 15726371
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase I study of E7010.
    Yamamoto K; Noda K; Yoshimura A; Fukuoka M; Furuse K; Niitani H
    Cancer Chemother Pharmacol; 1998; 42(2):127-34. PubMed ID: 9654112
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Population pharmacokinetics of the photodynamic therapy agent 2-[1-hexyloxyethyl]-2-devinyl pyropheophorbide-a in cancer patients.
    Bellnier DA; Greco WR; Loewen GM; Nava H; Oseroff AR; Pandey RK; Tsuchida T; Dougherty TJ
    Cancer Res; 2003 Apr; 63(8):1806-13. PubMed ID: 12702566
    [TBL] [Abstract][Full Text] [Related]  

  • 11. beta-Glucosidase activity in fetal bovine serum renders the plant glucoside, hypoxoside, cytotoxic toward B16-F10-BL-6 mouse melanoma cells.
    Theron EJ; Albrecht CF; Kruger PB; Jenkins K; van der Merwe MJ
    In Vitro Cell Dev Biol Anim; 1994 Feb; 30A(2):115-9. PubMed ID: 8012653
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High-performance liquid chromatographic method for the quantitative determination of Hypoxoside in African potato (Hypoxis hemerocallidea) and in commercial products containing the plant material and/or its extracts.
    Nair VD; Kanfer I
    J Agric Food Chem; 2006 Apr; 54(8):2816-21. PubMed ID: 16608194
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase I trial of the cryptophycin analogue LY355703 administered as an intravenous infusion on a day 1 and 8 schedule every 21 days.
    Stevenson JP; Sun W; Gallagher M; Johnson R; Vaughn D; Schuchter L; Algazy K; Hahn S; Enas N; Ellis D; Thornton D; O'Dwyer PJ
    Clin Cancer Res; 2002 Aug; 8(8):2524-9. PubMed ID: 12171879
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Influence of the antacid Maalox on the pharmacokinetics of capecitabine in cancer patients.
    Reigner B; Clive S; Cassidy J; Jodrell D; Schulz R; Goggin T; Banken L; Roos B; Utoh M; Mulligan T; Weidekamm E
    Cancer Chemother Pharmacol; 1999; 43(4):309-15. PubMed ID: 10071982
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetics of mycophenolic acid and its phenolic-glucuronide and ACYl glucuronide metabolites in stable thoracic transplant recipients.
    Ting LS; Partovi N; Levy RD; Riggs KW; Ensom MH
    Ther Drug Monit; 2008 Jun; 30(3):282-91. PubMed ID: 18520599
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Population pharmacokinetics of APOMINE: a meta-analysis in cancer patients and healthy males.
    Bonate PL; Floret S; Bentzen C
    Br J Clin Pharmacol; 2004 Aug; 58(2):142-55. PubMed ID: 15255796
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Population pharmacokinetics of a HER2 tyrosine kinase inhibitor CP-724,714 in patients with advanced malignant HER2 positive solid tumors.
    Guo F; Letrent SP; Sharma A
    Cancer Chemother Pharmacol; 2007 Nov; 60(6):799-809. PubMed ID: 17285315
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase I and pharmacologic study of intermittently administered 9-nitrocamptothecin in patients with advanced solid tumors.
    Zamboni WC; Jung LL; Egorin MJ; Potter DM; Friedland DM; Belani CP; Agarwala SS; Wong MM; Fakih M; Trump DL; Jin R; Strychor S; Vozniak M; Troetschel M; Ramanathan RK
    Clin Cancer Res; 2004 Aug; 10(15):5058-64. PubMed ID: 15297407
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Population pharmacokinetics of PM00104 (Zalypsis(®)) in cancer patients.
    Pérez-Ruixo C; Valenzuela B; Fernández Teruel C; González-Sales M; Miguel-Lillo B; Soto-Matos A; Pérez-Ruixo JJ
    Cancer Chemother Pharmacol; 2012 Jan; 69(1):15-24. PubMed ID: 21590449
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Linagliptin, a dipeptidyl peptidase-4 inhibitor in development for the treatment of type 2 diabetes mellitus: a Phase I, randomized, double-blind, placebo-controlled trial of single and multiple escalating doses in healthy adult male Japanese subjects.
    Sarashina A; Sesoko S; Nakashima M; Hayashi N; Taniguchi A; Horie Y; Graefe-Mody EU; Woerle HJ; Dugi KA
    Clin Ther; 2010 Jun; 32(6):1188-204. PubMed ID: 20637971
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.